- Inovio Pharmaceuticals Inc. (NASDAQ: INO) recedes from tops near $34.00.
- NASDAQ: INO plans to start the Phase 2/3 in the next couple of months.
Shares of Inovio Pharmaceuticals (NASDAQ: INO) have opened Tuesday’s session with strong losses and are partially fading Monday’s sharp advance to the boundaries of the $34.00 mark, or fresh YTD highs.
NASDAQ: INO recently announced that it will start its studies of Phase 2 and 3 over the summer, all following recent positive news that its Phase 1 study showed that all of the participants in the clinical trial of its coronavirus vaccine candidate was well tolerated.
Investors, however, appear somewhat disappointed on Tuesday after the pharmaceutical company did not disclosure the results of the participants’ antibody response.
On the broader scenario, the coronavirus pandemic is far from over in the US, where many states continue to report record cases of infected cases, all amidst the ongoing efforts to re-open the economic activity and to return to some sort of normality.
INO Stock Quote
As of writing and following the opening bell in Wall St., NASDAQ: INO is down 6.8% at $29.53 and faces the next support at $26.06 (low Jun.30) seconded by $14.21 (55-day SMA) and finally $10.73 (100-day SMA). On the flip side, the initial hurdle is located at £33.79 (2020 high Jun.26).
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.